EnduraCell™ for Diabetes
Type 1 Diabetes
Key Facts
About Likarda
Likarda is a private, revenue-generating biotech company founded in 2012 that operates as a technology platform and services partner. Its patented Core-Shell Spherification® (CSS®) hydrogel encapsulation platform is designed to protect therapeutic payloads, enable controlled release, and improve outcomes for cell therapies, biologics, and small molecules. The company has built a portfolio of branded solutions (e.g., ViscoCell™, EnduraCell™, LiberaCell™, NovoSphere™) with demonstrated preclinical success and is scaling its capabilities, including launching proprietary equipment and an AI-driven formulation platform in 2025. Likarda's business model centers on partnering with and providing enabling technologies to other therapeutic developers.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |